摘要
目的评估全视网膜光凝术联合康柏西普玻璃体腔注药治疗缺血型视网膜中央静脉阻塞继发新生血管性青光眼的临床疗效。方法回顾性分析2016年1月至2022年6月在解放军总医院第七医学中心眼科就诊的41例(41眼)缺血型视网膜中央静脉阻塞继发新生血管性青光眼患者的临床资料,均为单眼发病,年龄51~77岁,平均(60.9±11.2)岁,给予玻璃体腔注射康柏西普联合全视网膜光凝治疗。观察治疗前后的最佳矫正视力、眼压、新生血管消退情况及黄斑中心凹厚度。结果治疗前与治疗后1个月视力比较差异无统计学意义(P>0.05)。术后41眼虹膜及房角新生血管均发生不同程度的萎缩消退。治疗前及治疗后1周、1个月、3个月时的眼压分别为(34.6±4.9)mmHg及(28.3±5.8)mmHg、(24.9±4.0)mmHg、(23.6±3.4)mmHg,治疗后眼压逐渐降低,差异有统计学意义(P<0.05)。治疗后1周黄斑中心凹厚度明显低于治疗前,差异有统计学意义(P<0.05),而治疗后1个月时的黄斑中心凹厚度与治疗前及治疗后1周时比较差异无统计学意义(P>0.05)。结论全视网膜光凝联合康柏西普玻璃体注药可降低缺血型视网膜中央静脉阻塞继发新生血管性青光眼的眼压,并能减轻黄斑区囊样水肿。
Objective To evaluate the effect of the treatment which combined panretinal photocoagulation with intravitreous injection of Conbercept.This treatment is to treat the neovascular glaucoma caused by ischemic central retinal vein occlusion.Method From January,2016 to June,2022,41 patients with neovascular glaucoma caused by ischemic central retinal vein occlusion received the treatment.These patients aging from 55 to 77(60.9±11.2).Before and after the treatment these patients’best corrected visual acuity(BCVA),intraocular pressure(Iop),iris neovascularization and central macular thickness were observed.Result Before and one month after the treatment,there was no statistical difference(t=-1.500,P>0.05)in visual acuity.After the treatment,irises of 41 patients and neovascularization withered to a varying extent.Before the treatment the value of the Iop was(34.6±4.9)mmHg.The value of the Iop was(28.3±5.8)mmHg one week after the treatment.The value of the Iop was(24.9±4.0)mmHg one month after the treatment.Three months after the treatment the value became(23.6±3.4)mmHg.Before and after the treatment there was statistical difference(P<0.05).One week after the treatment the value of the central macular thickness is much lower than the value before the treatment,which showed a statistical difference(P<0.05).Compared to the value before treatment,the value of the central macular thickness one month after the treatment showed no statistical difference(P>0.05).Conclusion The treatment combining panretinal photocoagulation with intravitreous injection of Conbercept can reduce the intraocular pressure,and control the disease progression of neovascular glaucoma which is caused by ischemic central retinal vein occlusion,meanwhile the macular edema can be reduced.
作者
侯彬
张惠敏
张燕
Hou Bin;Zhang Huimin;Zhang Yan(Seventh Medical Center of Chinese PLA General Hospital,Beijng 100700,China)
出处
《中国医刊》
CAS
2024年第7期755-758,共4页
Chinese Journal of Medicine
基金
首都特色基金项目(z171100001017163)。
